Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by argeliomon Nov 18, 2020 12:35pm
191 Views
Post# 31922922

RE:RE:RE:RE:BioPub

RE:RE:RE:RE:BioPub 
To further elaborate regarding the use of NMDA receptors inhibitors such as ifenprodil in cancer treatment, I found the following 2019 article from Sweden.
"Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning": by Beste Turanli et.al.
https://www.workcast.com/ControlUsher.aspx?cpak=5155519046589836&pak=3511162085644479

The team reconstructed a prostate specific GEM which stands for Genome scale metabolic model (fear not, the article explains it). They examined 683 existing drugs which were initially paired down to 23 potential candidates for prostate cancer of which 12 had already been associated or tested for prostate cancer treatment. Out of the remaining 11 drugs previously not identified as anti-cancer agents, 8 showed a decrease in tumor growth. Lastly, after silico cell viability testing 4 were identified as novel candidates against prostate cancer. Ifenprofil showed the best effect by significantly reducing all 3 cancer cell lines. The article also states that other studies have found NMDA inhibitors drugs such as ifenprodil to have inhibitory effects on: esophageal,ovarian and pancratic cancers.


<< Previous
Bullboard Posts
Next >>